Indication
Autoimmune Disorders
2 clinical trials
1 product
3 drugs
Clinical trial
Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI)Status: Recruiting, Estimated PCD: 2025-10-29
Product
DaratumumabClinical trial
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersStatus: Not yet recruiting, Estimated PCD: 2028-12-31
Drug
TafasitamabDrug
fludarabineDrug
cyclophosphamide